Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A1 | P18405 | 2/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | LSS | P48449 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.46 |
| ▸ | HTR3A | P46098 | 1/20 | 0.44 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23134213 | 0.84 | LSS (0.60) | SRD5A1DRD2LSSSLC6A3SLC6A2 | |
| SCHEMBL8082343 | 0.84 | LSS (0.60) | SRD5A1DRD2LSSSLC6A3SLC6A2 | |
| SCHEMBL11314494 | 0.83 | DRD2 (0.46) | SRD5A1DRD2LSSSLC6A3SLC6A2 | |
| SCHEMBL11314498 | 0.83 | DRD2 (0.46) | SRD5A1DRD2LSSSLC6A3SLC6A2 | |
| SCHEMBL11314491 | 0.83 | DRD2 (0.46) | SRD5A1DRD2LSSSLC6A3SLC6A2 | |
| SCHEMBL13416033 | 0.81 | LSS (0.74) | SRD5A1DRD2LSSSLC6A3SLC6A2 | |
| SCHEMBL16846492 | 0.79 | SRD5A1 (0.46) | SRD5A1DRD2LSSSLC6A3SLC6A2 | |
| SCHEMBL15492553 | 0.79 | SLC6A2 (0.44) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7239508 | 0.78 | LSS (0.73) | SRD5A1DRD2LSSSLC6A3 | |
| SCHEMBL23978587 | 0.78 | DRD2 (0.58) | SRD5A1DRD2LSSSLC6A3HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-05-09 | — | — | US | disclosed |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-12-29 | — | — | US | disclosed |
| WO-2021222789-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20200172518-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | MISSION THERAPEUTICS LIMITED (GB) | 2020-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11643388-B2 | Inhibitors of alpha 2 beta 1 integrin and methods of use thereof | ITGB1, ITGB2, ITGA2 | SRD5A1 2451/4885DRD2 2870/4885LSS 2691/4885 |
| US-20200172518-A1 | SULFONAMIDE-SUBSTITUTED CYANOPYRROLIDINES WITH ACTIVITY AS DUB INHIBITORS | USP30, USP1, USP39 | SRD5A1 2276/4885DRD2 4570/4885LSS 3032/4885 |
| US-20220411366-A1 | INHIBITORS OF ALPHA 2 BETA 1 INTEGRIN AND METHODS OF USE THEREOF | ITGB1, ITGB2, ITGA2 | SRD5A1 2451/4885DRD2 2870/4885LSS 2691/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.